Trial52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
Trial details
- Registry ID
- NCT06689085
- Phase
- Phase 3
HALO
Halozyme Therapeutics
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
1Trials in this database
1Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| 52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With HypogonadismNCT06689085 | Halozyme Therapeutics | Phase 3 | Recruiting | 2028-03Estimated |
Latest recorded trial changes
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
NCT06689085 · Halozyme Therapeutics
Primary completion date changed
− Before
Oct 2027
+ After
Mar 2028